Medigen Vaccine’s Enterovirus 71 Vaccine Gains Regulatory Review in Singapore

Medigen Vaccine Biologics Corp. Has submitted its New Drug Application (NDA) for Enjian (Envacgen) Enterovirus 71 (EV71) vaccine to the Health Sciences Authority (HSA) of Singapore, marking a significant step towards expanding access to this crucial vaccine in Southeast Asia. This submission aligns with the company’s broader strategy to pursue regulatory approvals in key markets and address the growing need for EV71 vaccination, particularly in the wake of increased outbreaks following disruptions caused by the COVID-19 pandemic.

Understanding Enterovirus 71 and the Need for Vaccination

Enterovirus 71 is a highly neurotropic and pathogenic virus, a primary cause of hand, foot, and mouth disease (HFMD) and a significant concern in Southeast Asia. EV71 can lead to severe complications, including limb paralysis, encephalitis, meningitis, pulmonary edema, and hemorrhage, especially in children under five years old. The World Health Organization (WHO) recognizes the severity of EV71 and has been involved in developing recommendations to assure the quality, safety, and efficacy of EV71 vaccines.

Envacgen Vaccine: Efficacy and Development

The Envacgen EV71 vaccine is designed for active immunization of infants and young children aged 2 months to under 6 years to prevent diseases caused by EV71 infection. Clinical trials have demonstrated a 100% efficacy rate (96.8% in statistical Poisson regression analysis) against EV71, including major genetic subtypes prevalent in Southeast Asia. These findings were published in the prestigious medical journal, The Lancet, and further supported by long-term tracking data published in Vaccines, confirming antibody concentrations remain maintained for at least five years post-vaccination.

Key Milestones in Envacgen’s Development

• 2019: Phase 3 clinical trial initiated, enrolling 3,049 subjects.
• 2021/4/10: Immunogenicity data met the primary endpoint.
• 2021/6/10: Vaccine efficacy endpoint met.
• 2021/10/1: New Drug Application (NDA) submitted to the Taiwan Food and Drug Administration (TFDA).
• 2023/4/13: TFDA granted marketing authorization.
• 2023/8/8: Vaccine officially launched in Taiwan.

Singapore’s Regulatory Landscape and Market Potential

Singapore’s Health Sciences Authority (HSA) is a national regulatory agency with the highest rating (Maturity Level 4 – ML4) from the WHO. Approval from the HSA carries significant weight for expanding market access within the ASEAN region. Currently, Singapore does not have a locally approved EV71 vaccine. HFMD, caused by enterovirus infection, is a significant public health concern in Singapore, subject to strict epidemiological surveillance by the Ministry of Health.

Future Outlook

Following the successful launch in Taiwan and the submission to Singapore, Medigen Vaccine is actively pursuing regulatory approvals in other key markets, including Vietnam, where Phase 3 clinical trials are underway. The company anticipates continued growth in the international market for its EV71 vaccine, driven by the increasing prevalence of EV71 infections and the growing demand for preventative measures, particularly in light of immunization debt following the COVID-19 pandemic. The company will disclose accumulated research and development expenses at a later date due to business strategic considerations.

Disclaimer: The development of new drugs involves inherent risks and uncertainties, and there is no guarantee of success. Investors should exercise caution and conduct thorough due diligence before making investment decisions.